申请人:National Science Council
公开号:US05594033A1
公开(公告)日:1997-01-14
Novel secoaporphine compounds having the formula I ##STR1## wherein a) R.sub.1, R.sub.2 and R.sub.3, R.sub.4 are each methyl group; or b) R.sub.1, R.sub.2, and R.sub.4 are each methyl group; R.sub.3 is benzyl, ethyl or allyl; or c) R.sub.1, R.sub.2, and R.sub.3 are each hydrogen, R.sub.4 is methyl; or d) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is benzyl, R.sub.4 is methyl; or e) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is cyano, R.sub.4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.
具有以下结构式I的新型咔啉类化合物:##STR1## 其中a)R.sub.1、R.sub.2和R.sub.3、R.sub.4均为甲基基团;或b)R.sub.1、R.sub.2和R.sub.4均为甲基基团;R.sub.3为苄基、乙基或丙烯基;或c)R.sub.1、R.sub.2和R.sub.3均为氢,R.sub.4为甲基;或d)R.sub.1和R.sub.2均为氢,R.sub.3为苄基,R.sub.4为甲基;或e)R.sub.1和R.sub.2均为氢,R.sub.3为氰基,R.sub.4为甲基基团,并且其与药学上可接受的酸的盐在心律失常治疗中有用。